Photocrosslinked poly(ester anhydride)s for peptide delivery: Effect of oligomer hydrophobicity on PYY3-36 delivery

Juha Mönkäre a,⇑,1, Risto A. Hakala b,1, Miia Kovalainen a, Harri Korhonen b, Karl-Heinz Herzig c,d, Jukka V. Seppälä b,1, Kristiina Järvinen a

a School of Pharmacy, University of Eastern Finland, Kuopio, Finland
b Polymer Technology, School of Chemical Technology, Aalto University, Aalto, Finland
1 Institute of Biomedicine and Biocenter of Oulu, University of Oulu, Oulu, Finland
c Department Psychiatry, Kuopio University Hospital, Kuopio, Finland

ARTICLE INFO

Article history:
Received 25 May 2011
Accepted in revised form 15 September 2011
Available online 22 September 2011

Keywords:
Poly(ester anhydride)
Photocrosslinking
Peptide YY3-36
Controlled release
Bioavailability
Pharmacokinetics

ABSTRACT

The treatment for many diseases can be improved by developing more efficient peptide delivery technologies, for example, biodegradable polymers. In this work, photocrosslinked poly(ester anhydride)s based on functionalized poly(ε-caprolactone) oligomers were investigated for their abilities to achieve controlled peptide delivery. The effect of oligomer hydrophobicity on erosion and peptide release from poly(ester anhydride) was evaluated by developing a sustained subcutaneous delivery system for an antiobesity drug candidate, peptide YY3-36 (PYY3-36). Oligomer hydrophobicity was modified with alkenylsuccinic anhydrides containing a 12-carbon alkenyl chain. PYY3-36 was mixed as a solid powder with methacrylated poly(ester anhydride) precursors, and this mixture was photocrosslinked at room temperature to form an implant for subcutaneous administration in rats. The oligomer hydrophobicity controlled the polymer erosion and PYY3-36 release as the increased hydrophobicity via the alkenyl chain prolonged polymer erosion in vitro and sustained in vivo release of PYY3-36. In addition, photocrosslinked poly(ester anhydride)s increased the bioavailability of PYY3-36 by up to 20-fold in comparison with subcutaneous administration of solution, evidence of remarkably improved delivery. In conclusion, this work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for use in peptide delivery.

1. Introduction

Proteins and peptides are promising candidates for drug therapy in many therapeutic areas. However, they are still often formulated as suspensions or aqueous solutions that do not always allow the most efficient delivery of macromolecules [1]. Therefore, more sophisticated delivery systems need to be developed, i.e., to achieve sustained and controlled release [2,3] or protection against drug degradation at the site of administration [4,5].

Surface-erosion-controlled delivery systems hold great potential for peptide administration since the unreleased peptide is kept intact inside the polymer matrix and the peptide release rate is directly proportional to the polymer erosion rate [6]. Recently, we have investigated photocrosslinked poly(ester anhydride)s for their potential in achieving surface-erosion-controlled drug delivery [7,8]. These biodegradable and biocompatible polymers combine favorably the beneficial properties of the polyesters and polyanhydrides, such as good mechanical strength of polyesters [9] with the surface erosion property of polyanhydrides [10]. One of the advantages of these poly(ester anhydride)s is the flexibility offered by the possibility for the modification of oligomer chemistry. As an example, changing the oligomer hydrophobicity [11] can alter the polymer erosion and drug release rates. If one wishes to fabricate photocrosslinked poly(ester anhydride) devices, then the drug can be mixed as a solid powder with viscous liquid precursors at room temperature without the need for solvents, and by using a low-energy light source, one can avoid the unnecessary increase in the temperature. In addition, the drug loading degree and device dimensions can be varied extensively, and also injectable poly(ester anhydride) implants can be prepared.

Weight management is an example of a therapeutic application that could significantly benefit from more efficient peptide delivery technologies. Obesity is a growing global public health problem, and peptide YY3-36 (PYY3-36) is one of the most promising drug candidates for its treatment [12]. PYY3-36 is an endogenous gut hormone, secreted from L-cells in the gastrointestinal tract, which regulates energy metabolism in many ways, for example, by inducing satiety [12,13]. Previously, intravenous (i.v.) adminis-
tration of PYY3-36 has been shown to reduce food intake in animals and humans [14–16] and to lower bodyweight in animals [17,18]. Due to its promising properties for the treatment of obesity, different delivery systems have been explored for PYY3-36, e.g., the intranasal [19] and peroral [20] routes. However, despite their many advantages, such as ease of dosing, these delivery systems have also disadvantages, such as evoking adverse effects or achieving inadequate therapeutic response. In a 12-week trial, intranasal administration before meals did not induce weight loss and a higher dose evoked adverse effects, such as nausea and vomiting [19]. The peroral route has been shown to be well tolerated but PYY3-36 only appeared to be able to reduce the caloric intake when administered with GLP-1 before a meal [20]. Interestingly, subcutaneous (s.c.) injections of PYY3-36 solution have been shown to increase the feelings of satiety and to decrease hunger in obese males with minimal adverse effects despite the presence of higher plasma concentrations than obtained after intranasal administration [19,21]. In addition, administration via the s.c. route produced an elevation of PYY plasma concentrations for more than 4 h, which was speculated to evoke a long-lasting appetite-suppressive effect [21].

In this work, the suitability of photocrosslinked poly(ester anhydride)s for controlled peptide delivery was evaluated by developing a sustained s.c. delivery system for PYY3-36 ($M_w$ 4050 g/mol). The poly(ester anhydride) oligomers were functionalized with succinic anhydride (SAH) or with the more hydrophobic alkenylsuccinic anhydride (12-ASA) containing a 12-carbon alkynyl chain in order to clarify the effect of oligomer hydrophobicity on peptide delivery.

2. Materials and methods

2.1. Materials

Oligomers were polymerized from ε-caprolactone (Solvay Interox Ltd., Warrington, England) in the presence of stannous octoate and pentaerythritol. The ε-caprolactone was redistilled and dried over molecular sieves. Stannous octoate as an initiator and pentaerythritol as a co-initiator were used in the ring-opening polymerization of the oligomers. Succinic anhydride (SAH), 2-dodecen-1-ylsuccinic anhydride (12-ASA), and methacrylic anhydride were used in the functionalizations, and camphorquinone was used as an initiator for photocuring. All reagents except ε-caprolactone were purchased from Sigma–Aldrich Chemie, Germany, and were used as received.

Human peptide YY3-36 ($M_w$ 4050 g/mol) was purchased from BCN Peptides (Barcelona, Spain). In the in vitro drug release study, phosphate-buffered solution, pH 7.4 (0.2 M NaOH–KH$_2$PO$_4$) was prepared using NaOH from FF-Chemicals (Yli-Ii, Finland) and KH$_2$PO$_4$ from Merck (Darmstadt, Germany). Bovine serum albumin (BSA, Sigma–Aldrich, St. Louis, MO, USA) (0.1% w/v) was dissolved in the buffer in order to prevent the adsorption of PYY3-36 onto the laboratory materials during the in vitro experiment. Sodium chloride solution (9 mg/ml) for injections was obtained from B. Braun Melsungen AG (Melsungen, Germany) and Baxter Oy (Vantaa, Finland).

2.2. Animals

Male Wistar rats (age of 8–12 weeks, 293–398 g, mean 328 g) (Kuopio, Finland) were housed in an environment-controlled room temperature 21 ± 1°C, relative air humidity 55 ± 15%, and 12/12 h light/dark cycle with lights on at 7 AM with food (Teklad 2016, Harlan Inc.) and tap water available ad libitum. The National Animal Experiment Board of Finland approved the experiments. Procedures were conducted in accordance with the guidelines set by the Finnish Act on Animal Experimentation (62/2006) and European Community Council Directives 86/609/EEC.

2.3. Preparation of poly(ester anhydride) implants

The synthesis and properties of the poly(ester anhydride) based on poly(ε-caprolactone) oligomers have been described earlier [11,22], and the main features are shown in Scheme 1. Briefly, ε-caprolactone monomers were polymerized to star-shaped hydroxyl telechelic oligomers by ring-opening polymerization. In the next step, the hydroxyl termination was changed to acid termination with succinic anhydride (SAH) or 2-dodecen-1-ylsuccinic anhydride (12-ASA). In order to obtain crosslinkable poly(ester anhydride) precursors with labile anhydride bonds, acid-terminated oligomers were allowed to react with methacrylic anhydride.

In the photocrosslinking, the viscous liquid methacrylated precursors, camphorquinone (1% w/w) with and without PYY3-36 powder (1% w/w) were stirred until homogeneity was achieved and the mixture was then placed into a mold in order to produce the implants (2 mm in thickness, 5 mm in diameter, and 50 mg in weight). Photocrosslinking was done using visible light (1 W, 16 mW/cm$^2$) at room temperature for 20 min. The mean PYY3-36 doses were 525 and 483 μg/implant for SAH- and 12-ASA-functionalized implants, respectively.

The gel contents of the photocured implants were measured by extracting the soluble phase in dichloromethane at room temperature for 24 h, and it was found that gel contents were >95%. Attenuated total reflectance infrared spectroscopy (ATR-FTIR, Nicolet Magna-FTIR spectrometer 750 equipped with Pike Technologies GladiATR with diamond crystal plate) was used to monitor the double bond conversion of the methacrylated precursors. The double bond conversion in the implants was calculated based on the decrease in absorbance near 1637 cm$^{-1}$, a characteristic absorbance of the methacrylate double bond [22,23]. The final double bond conversions were >93%.

2.4. In vitro erosion of implants

The in vitro erosion ($n = 3$) of the poly(ester anhydride) implants was studied in 40 ml of pH 7.4 phosphate buffer in the water bath shaker with orbital shaking at a frequency of 120 strokes/min at +37°C (Grant OLS200, Cambridge, UK). Samples were removed from the buffer at predetermined time intervals and dried in a vacuum for 48 h prior to weighing. The erosion (%) was calculated by dividing the dried weight of the sample by its initial weight.

2.5. In vitro release of PYY3-36

The in vitro release ($n = 3$) from the SAH- and 12-ASA-functionalized poly(ester anhydride) implants was studied by using USP Apparatus I (basket) under sink conditions. The buffer (pH 7.4, +37°C) volume was 400 ml, and the rotation speed of the basket was 50 rpm (Sotax AT6, Sotax AG, Basel, Switzerland). Samples (2 ml) were collected at predetermined time intervals, and the sampling volume was replaced by fresh prewarmed buffer. The released PYY3-36 in the buffer was analyzed using total human PYY ELISA kit (Millipore Corp., Billerica, MA, USA) according to the manufacturer’s instructions.

2.6. In vivo delivery of PYY3-36

One photocrosslinked poly(ester anhydride) implant was implanted subcutaneously in the back of each rat. In addition to the PYY3-36-loaded SAH- and 12-ASA-functionalized implants ($n = 6$), peptide-free SAH-functionalized ($n = 4$) and 12-ASA-functionalized ($n = 3$) implants were implanted and three rats were sham-operated.
Maximum plasma concentration (C_max) and time to reach C_max values (t_max) were obtained directly from the plasma concentration–time data. Terminal half-life (t_1/2) was calculated as 0.693/K_e, where K_e is the terminal elimination rate constant. The area under the concentration–time curve values (AUC_0–last) until the last measured plasma concentration (C last) were determined by the linear trapezoidal rule, and AUC_0–∞ was determined as AUC_0–last + C last/K_e. Clearance (CL) and volume of distribution (V_d) were calculated as D/AUC_0–∞ and D/(K_e · AUC_0–∞), where D is dose. Absolute bioavailability (%F) was calculated as (AUC e.v./AUC i.v.) · (D e.v./D i.v.) · 100%, where AUC e.v. and AUC i.v. are AUC_0–∞ values of extravascular and i.v. administration, respectively, and D e.v. and D i.v. are the corresponding doses for extravascular and i.v. administration. Relative s.c. bioavailability (%Frel) was calculated by using AUC_0–∞ values and doses of s.c. solution (s.c.) poly(ester anhydride) (PEAH) administration as follows: [AUCPEAH/AUC e.v.] · (D c.ev./D PEAH) · 100%. In vivo release and absorption profile based on percent AUC values (AUC%) were determined as (AUC_0–1/AUC_0–∞) · 100% [24].

2.8. Statistical analysis

Mann–Whitney U test was used to compare the statistical differences of PYY3-36 between pharmacokinetic parameters of two groups (i.v., s.c., or implant administration) [GraphPadPrism 5.03 for Windows, GraphPad Software, San Diego, CA, USA, www.graphpad.com]. Kruskal–Wallis (SPSS 14.0 for Windows, SPSS Inc.) with post hoc test [25] was used to compare statistical differences between multiple groups. The level of significance was set at p < 0.05.

3. Results

3.1. In vitro erosion of implants and PYY3-36 release

The increase in oligomer hydrophobicity by the introduction of alkenylsuccinic anhydride with 12-carbon alk enyl chain (12-ASA) slowed down the erosion of photocrosslinked peptide-free poly (ester anhydride) implants (Fig. 1). 12-ASA-functionalized poly(ester anhydride) implants eroded in 72 h and the erosion rate was 1.7 ± 0.01%/h with a 12 h lag time. Peptide-free SAH-functionalized poly(ester anhydride) eroded in 48 h with the rate of 2.0 ± 0.04%/h without any lag time, as reported earlier [8]. Irrespective of the degree of hydrophobicity, both poly(ester anhydride) implants exhibited surface-eroding characteristics.

The in vitro release of PYY3-36 was also affected by the oligomer hydrophobicity. PYY3-36-loaded SAH-functionalized implants released PYY3-36 completely in vitro in 24 h showing a linear release rate of 4.5 ± 0.33%/h without any lag time (Fig. 2 and Table 1). However, the fraction of PYY3-36 released from 12-ASA functionalized in vitro was less than 20% in 60 h, although implants were completely eroded within that time (Fig. 2). One explanation for this result could be that poorly soluble degradation products of 12-ASA-functionalized poly(ester anhydride) had been deposited on the implant surface and PYY3-36 was interfering with this film-like layer [26,27].

3.2. In vivo delivery of PYY3-36

I.v. administration of 2 and 20 µg of PYY3-36 exhibited linear pharmacokinetics of PYY3-36, based on first-order elimination kinetics as presented in Table 2 and Fig. 51 of Supplementary data. The terminal elimination half-lives (t_1/2) of PYY3-36 were approximately 40 min, which is slightly longer than earlier reported values for mice (13 min) [28] or rabbits (13–19 min) [17]. The AUC values achieved with 2 µg and 20 µg i.v. doses of PYY3-36 were compared, and the difference in values was only 6-fold instead of the expected

---

2.7. Pharmacokinetic analysis

Pharmacokinetic parameters for PYY3-36 were determined from plasma concentration–time data by using WinNonlin software (WinNonlin Professional, 5.3, Pharsight Corp, USA) and non-compartmental model for extravascular and bolus intravenous injection in the cases of s.c. and i.v. administration, respectively, and with uniform weighing. All data are presented as mean ± SEM.
10-fold increase, based on the assumption of linear pharmacokinetics. A comparison of primary pharmacokinetic parameters between doses showed that values for volume of distribution (Vd, p < 0.05) and clearance (CL) were smaller after 2 than after 20 µg dose. However, the ratio of Vd to CL remained constant, and therefore, changes did not affect the terminal half-lives.

S.c. administration of PYY3-36 solution displayed evidence of limited s.c. absorption of PYY3-36. The absolute bioavailability (F%) values were low and dose-dependent, being 17.9 ± 6.2% and 6.3 ± 1.1% for 2 and 20 µg doses, respectively (Table 2). Furthermore, the difference between AUC(0-∞) values of 2 and 20 µg doses was only 1.8-fold, indicating that the extent of s.c. absorption of PYY3-36 declined as the dose increased. In contrast, the dose did not affect significantly the absorption rate, i.e., t_{max} and the shape of plasma concentration–time profile (Table 2, Fig. S1). Elimination half-lives after s.c. administration were 42 ± 4.2 min and 78 ± 24.0 min for 2 and 20 µg doses, respectively, that are comparable to the literature values for non-parenteral administration in humans (per oral 24–50 min) [29] or rabbits (intranasal 34–40 min) [30].

In contrast to s.c. administration of PYY3-36 solution, PYY3-36 was absorbed nearly completely into the systemic circulation from the photocrosslinked poly(ester anhydride) implants (Table 2). The bioavailabilities of PYY3-36 administered in SAH-functionalized or 12-ASA-functionalized poly(ester anhydride) implants were 81 ± 13.2% (131 ± 21.5%) and 71 ± 20.4% (116 ± 33.1%) when compared with 2 µg (or 20 µg) i.v. doses, respectively, (Table 2). Significant differences (p < 0.05) between absolute bioavailabilities of 20 µg s.c. solution and poly(ester anhydride) implants were found. Furthermore, the relative s.c. bioavailabilities (F_{rel}) of PYY3-36 from the photocrosslinked poly(ester anhydride) implants ranged from 330% to 2070%, which indicated that there was 3- to 20-fold higher absorption from implants than from s.c. solution injection (Table 2). These results demonstrate that photocrosslinked poly(ester anhydride)s can significantly improve PYY3-36 delivery in comparison with the solution administration.

PYY3-36 administration via s.c. implanted photocrosslinked poly(ester anhydride)s significantly sustained the release of the peptide. After administration in solution, PYY3-36 was detected in plasma for only 4 h, whereas peptide administration via poly(ester anhydride) implants prolonged the detection period up to 9 days (Fig. 3). The duration of the in vivo release was analyzed by the percent AUC method [24], which describes the drug input into systemic circulation by combining release and absorption phases. The comparison of SAH-functionalized and 12-ASA-functionalized implants indicated that hydrophobic modification with 12-carbon alkenyl chain sustained PYY3-36 release from 3 to 7 days (Fig. 3). In addition, the linear in vivo release rate halved from 2.0 ± 0.1%/h of SAH-functionalized to 1.0 ± 0.07%/h with the 12-ASA-functionalized implants. Similarly, oligomer modification with 12-ASA more than doubled the duration of the linear release phase from 46 to 102 h and prolonged the lag time from 22 ± 2.0 to 38 ± 4.8 h (Table 1). In addition, pharmacokinetic parameters describing the rate of absorption were affected by the oligomer modification, so that t_{max} was delayed from 42 ± 4.0 to 92 ± 4.0 h and C_{max} decreased from 72 ± 13.2 to 29 ± 10.3 ng/ml (Table 2). At the end of the experiments, rats were sacrificed and the implantation site was visually inspected. No traces of polymer could be detected in the tissue around the site, indicating that there had been complete erosion of the photocrosslinked poly(ester anhydride) implants.

4. Discussion

This work clearly demonstrates the suitability of photocrosslinked poly(ester anhydride)s for achieving peptide delivery such that the release rate of the peptide can be tailored by modifying the oligomer hydrophobicity of the poly(ester anhydride). These materials have potential for use in applications requiring controlled short-term release of macromolecular compounds.

The incorporation of a hydrophobic 12-carbon alkenyl chain into the oligomers decreased the erosion rate of the photocrosslinked poly(ester anhydride) implant in comparison with the implant without the alkenyl chain. This is in agreement with an earlier study done with thermoplastic poly(ester anhydride)s [7]. Since the drug release from photocrosslinked poly(ester anhydride)s is surface-erosion-controlled as discussed below, the change in the erosion rate had a direct effect on the release rate of PYY3-36. The 12-ASA-functionalization affected PYY3-36 in vitro release, which was incomplete even though the implant had been totally eroded. When degradations products of SAH- and 12-ASA-functionalized implants are compared, the only difference is their hydrophobicity due to 12-carbon alkenyl chain of 12-ASA-functionalized polymer (Scheme 1). Therefore, it is postulated that incomplete in vitro release is due to a hydrophobic interaction between PYY3-36 and hydrophobic moieties of degradation products of 12-ASA-functionalized polymer rather than an interaction between PYY3-36 and anhydride bonds. An earlier study demonstrated that in vitro degradation products of poly(ester anhydride) microspheres, i.e., fatty acid dimers, formed an interaction with...
implants (mean ± SEM, n = 3 (in vitro) or n = 6 (in vivo)).

Table 1

<table>
<thead>
<tr>
<th>Release rate (%/h)</th>
<th>R2 value of release</th>
<th>Duration of linear release (h)</th>
<th>Lag time of linear release (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAH-functionalized (in vitro)</td>
<td>4.5 ± 0.33</td>
<td>0.885 ± 0.029</td>
<td>24</td>
</tr>
<tr>
<td>SAH-functionalized (in vivo)</td>
<td>2.0 ± 0.10</td>
<td>0.984 ± 0.002</td>
<td>46 ± 2.0</td>
</tr>
<tr>
<td>12-ASA-functionalized (in vivo)</td>
<td>1.0 ± 0.07</td>
<td>0.975 ± 0.006</td>
<td>102 ± 7.4</td>
</tr>
</tbody>
</table>

Table 2

Pharmacokinetic parameters of PYY3-36 after i.v. and s.c. solution and SAH- and 12-ASA-functionalized photocrosslinked poly(ester anhydride) implant administration to rats (mean ± SEM, n = 4 for solutions and n = 6 for implants).

<table>
<thead>
<tr>
<th>Pharmacokinetic parameters</th>
<th>2 µg i.v.</th>
<th>20 µg i.v.</th>
<th>2 µg s.c.</th>
<th>20 µg s.c.</th>
<th>SAH-functionalized (525 µg)</th>
<th>12-ASA-functionalized (483 µg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (ng/ml)</td>
<td>26.8 ± 1.8a</td>
<td>187 ± 26.1a</td>
<td>0.98 ± 0.26b</td>
<td>3.5 ± 0.44b</td>
<td>72.0 ± 13.2c</td>
<td>29.2 ± 10.3b</td>
</tr>
<tr>
<td>tmax (h)</td>
<td>0.017</td>
<td>0.017</td>
<td>0.63 ± 0.13</td>
<td>0.25 ± 0.09</td>
<td>42.0 ± 4.0d</td>
<td>92.0 ± 4.0d</td>
</tr>
<tr>
<td>t1/2 (min)</td>
<td>38.8 ± 2.3</td>
<td>39.8 ± 4.1</td>
<td>42.3 ± 4.2</td>
<td>78.0 ± 24.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL (ml/h/kg)</td>
<td>771 ± 97.1</td>
<td>1240 ± 110</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vd (ml/kg)</td>
<td>712 ± 81.6</td>
<td>1160 ± 74.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUCₘ₀–₅₀ (ng/ml/kg)</td>
<td>27.0 ± 3.8</td>
<td>167 ± 15.1a</td>
<td>5.8 ± 1.7</td>
<td>8.7 ± 1.1</td>
<td>5750 ± 972</td>
<td>4760 ± 1390</td>
</tr>
<tr>
<td>AUCₘ₀–₅₀ (ng/ml/kg)</td>
<td>27.6 ± 3.7a</td>
<td>170 ± 15.8a</td>
<td>6.0 ± 1.7</td>
<td>10.7 ± 1.9</td>
<td>5830 ± 958</td>
<td>4790 ± 1400</td>
</tr>
<tr>
<td>F/i.v. (2 µg i.v.)</td>
<td>17.9 ± 6.2</td>
<td>3.9 ± 0.7b</td>
<td>80.5 ± 13.2c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F/i.v. (20 µg i.v.)</td>
<td>29.1 ± 10.0</td>
<td>6.3 ± 1.1</td>
<td>131 ± 21.5e</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F/s.c. (2 µg s.c.)</td>
<td>373 ± 61.2</td>
<td></td>
<td>330 ± 94.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F/s.c. (20 µg s.c.)</td>
<td>2070 ± 340</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Statistical differences:

* p < 0.05 2 µg i.v. vs. 20 µg i.v.
* p < 0.05 2 µg s.c. vs. 20 µg s.c.
* p < 0.05 SAH vs. 12-ASA.
* p < 0.01 SAH vs. 12-ASA.
* p < 0.01 20 µg s.c. vs. SAH and 12-ASA.

protein [31]. However, in vivo release of PYY3-36 was nearly complete from 12-ASA-functionalized poly(ester anhydride) implants, which leads to the conclusion that PYY3-36 and degradation products of 12-ASA-functionalized polymer are not interacting in the subcutaneous space.

In surface-erosion-controlled drug release, the physicochemical properties of the drug should not affect the release rate; this should be entirely controlled by polymer erosion. Earlier, propranolol HCl (4.5%/h) and SAH-functionalized implants were similar, indicating that the physicochemical properties of drugs did not influence the drug release. The tendency of in vitro release rates to be slightly higher than those measured in vivo can be explained by differences in water exposure, which is more limited in the subcutaneous space than in in vitro settings [32–34]. This can limit the polymer erosion based on the hydrolysis of anhydride bonds and consequently decrease the drug release rate.

Thus, although the physicochemical properties, particularly the molecular weights of PYY3-36 (4050 g/mol) and propranolol HCl (296 g/mol), differ considerably, their release rates from SAH-functionalized implants were similar, indicating that the physicochemical properties of drugs did not influence the drug release. The tendency of in vitro release rates to be slightly higher than those measured in vivo can be explained by differences in water exposure, which is more limited in the subcutaneous space than in in vitro settings [32–34]. This can limit the polymer erosion based on the hydrolysis of anhydride bonds and consequently decrease the drug release rate.

Although earlier PYY3-36 has been administered subcutaneously to rodents and humans [21,35,36], its s.c. bioavailability has not been reported. In this study, the s.c. bioavailability of PYY3-36 was low (3.9–29.1%) and dose-dependent after administration as a solution, when compared with the s.c. bioavailabilities of other peptides and proteins [37,38]. However, the s.c. bioavailability of the peptide was practically 100% when it was administered in photocrosslinked poly(ester anhydride) implants. It must be noted that the administered dose of PYY3-36 was not identical in the implants (~500 µg) and solutions (2–20 µg) and PYY3-36 showed dose-dependent s.c. absorption based on the comparison of s.c. bioavailability and AUC₀–₅₀ values of 2 and 20 µg doses. However, the dose-dependent absorption indicated that the higher the dose, the lower was the fraction absorbed, which is opposite to the difference in bioavailability when the comparison was between solution and implant administration. The fundamental difference between solution and implant administration is the availability of peptide for absorption. After the administration of solution, PYY3-36 was immediately available for absorption but with the implant, the release rate is controlled, such that the release rate is constantly 5–10 µg/h during the linear release phase. Based on differences in bioavailability between 2 and 20 µg doses in solution, and between implant and solution administration, it is postulated that this low and steady release rate would be beneficial for the absorption of PYY3-36. In addition, the unreleased peptide was located in the polymer matrix where it would be protected from degradation in the subcutaneous space [4,5]. Thus, it is proposed
that s.c. administration via a biodegradable polymer represents an efficient route for sustained and controlled PYY3-36 delivery.

5. Conclusion
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

Role of the funding source
Funding sources have had no involvement in the conduct of the research or preparation of the manuscript.

Acknowledgements
Pelka Savolainen (B.Sc. Pharm.) is acknowledged for his skilled technical assistance. The financial support from the Academy of Finland (PEPBI consortium # 117906) and Graduate School in Pharmaceutical Research (J.M.), Finnish Cultural Foundation (M.K.), and Orion Farmos Research Foundation (M.K.) is acknowledged.

Appendix A. Supplementary material

References
[3] G. Schwach, N. Oudry, J.P. Giliberto, P. Broqua, M. Luck, H. Lindner, R. Gurny, Poly(ester anhydrides) for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

5. Conclusion
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

Role of the funding source
Funding sources have had no involvement in the conduct of the research or preparation of the manuscript.

Acknowledgements
Pelka Savolainen (B.Sc. Pharm.) is acknowledged for his skilled technical assistance. The financial support from the Academy of Finland (PEPBI consortium # 117906) and Graduate School in Pharmaceutical Research (J.M.), Finnish Cultural Foundation (M.K.), and Orion Farmos Research Foundation (M.K.) is acknowledged.

Appendix A. Supplementary material

References
[3] G. Schwach, N. Oudry, J.P. Giliberto, P. Broqua, M. Luck, H. Lindner, R. Gurny, Poly(ester anhydrides) for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

5. Conclusion
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

Role of the funding source
Funding sources have had no involvement in the conduct of the research or preparation of the manuscript.

Acknowledgements
Pelka Savolainen (B.Sc. Pharm.) is acknowledged for his skilled technical assistance. The financial support from the Academy of Finland (PEPBI consortium # 117906) and Graduate School in Pharmaceutical Research (J.M.), Finnish Cultural Foundation (M.K.), and Orion Farmos Research Foundation (M.K.) is acknowledged.

Appendix A. Supplementary material

References
[3] G. Schwach, N. Oudry, J.P. Giliberto, P. Broqua, M. Luck, H. Lindner, R. Gurny, Poly(ester anhydrides) for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

5. Conclusion
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

Role of the funding source
Funding sources have had no involvement in the conduct of the research or preparation of the manuscript.

Acknowledgements
Pelka Savolainen (B.Sc. Pharm.) is acknowledged for his skilled technical assistance. The financial support from the Academy of Finland (PEPBI consortium # 117906) and Graduate School in Pharmaceutical Research (J.M.), Finnish Cultural Foundation (M.K.), and Orion Farmos Research Foundation (M.K.) is acknowledged.

Appendix A. Supplementary material

References
[3] G. Schwach, N. Oudry, J.P. Giliberto, P. Broqua, M. Luck, H. Lindner, R. Gurny, Poly(ester anhydrides) for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

5. Conclusion
This work demonstrates the suitability of photocrosslinked poly(ester anhydride)s for peptide delivery since by tailoring, the hydrophobicity of poly(ester anhydride) oligomers, peptide delivery, and polymer erosion rates could be modified. PYY3-36 bioavailability was increased clearly by using photocrosslinked poly(ester anhydride)s for s.c. administration of PYY3-36 when compared with its administration in solution. Therefore, s.c. administration via a biodegradable polymer is proposed to be an efficient route for PYY3-36 delivery.

Role of the funding source
Funding sources have had no involvement in the conduct of the research or preparation of the manuscript.

Acknowledgements
Pelka Savolainen (B.Sc. Pharm.) is acknowledged for his skilled technical assistance. The financial support from the Academy of Finland (PEPBI consortium # 117906) and Graduate School in Pharmaceutical Research (J.M.), Finnish Cultural Foundation (M.K.), and Orion Farmos Research Foundation (M.K.) is acknowledged.

Appendix A. Supplementary material